Towards selective peptide deformylase inhibitors: A mass spectrometry-based evaluation of in cellulo activity of actinonin and bromoindole derivatives

Peptide deformylase plays a crucial role in prokaryotic translation and constitutes an antibiotic target previously addressed in clinical trials. In eukaryotes, mitochondrial translation also relies on peptide deformylase, necessitating antibiotic development to aim for selective inhibition of the bacterial enzymes. In the present study, we investigated two compound series: derivatives of actinonin and compounds containing a 5-bromoindole scaffold. Antibacterial activity was evaluated by microdilution-based minimal inhibitory concentration assay and selectivity investigated using human peripheral blood mononuclear cells. In vitro peptide deformylase inhibition was compared for the Escherichia coli and human enzyme. To validate peptide deformylase inhibition in the bacterial cell, a mass spectrometric analysis directly coupled to the minimal inhibitory concentration assay was developed for the model organism Bacillus subtilis . Two compounds originating from this work ( ZHO-119 , ZHO-197 ) showed antibacterial activity comparable to actinonin. They both were highly for the bacterial enzyme selective in vitro and displayed no cytotoxicity. The mass spectrometry-based analysis indicates that in addition to peptide deformylase, ZHO-197 very effectively inhibits bacterial methionine aminopeptidase, the metallo-enzyme that removes the deformylated N-terminal methionine. • Peptide deformylase removes formyl group of N-terminal methionine co-translationally • Peptide deformylase is a promising antibiotic target not yet clinically exploited • We established in vitro and in vivo peptide deformylase inhibition assays • Actinonin derivatives with good antibacterial activity were discovered • ZHO-197 also impacts next processing step by methionine aminopeptidase